Migraine clinical trials are currently paying participants anywhere from $100 to over $1,000, depending on the study length, number of visits, and the drug being tested. If you suffer from migraines and have considered enrolling in a paid research study, the compensation landscape right now is genuinely worth exploring. For example, AutoCruitment-listed adult migraine studies offer up to $800 for completing all study visits, Santos Research Center in Tampa pays up to $450, and some pediatric migraine trials through Discovery Clinical Trials in San Antonio compensate families up to $1,680 for full participation. On top of the cash, nearly all trials provide no-cost study-related medical care and medication, which can be significant when you consider that individual migraine sufferers spend up to $11,010 per year in direct healthcare costs.
Roughly 39 million Americans live with migraines, a number that has held steady for three decades. Women are three times more likely than men to experience them after puberty, with about 43 percent of women affected over their lifetime compared to 18 percent of men. Despite how common the condition is, many people have no idea that pharmaceutical companies and research institutions will pay them to test new treatments. This article breaks down what these studies actually pay, where to find currently enrolling trials, what the eligibility requirements look like, which new drugs are in the pipeline, and what you should watch out for before signing up.
Table of Contents
- How Much Do Migraine Studies Actually Pay Participants?
- Where to Find Paid Migraine Clinical Trials Recruiting Right Now
- What New Migraine Treatments Are Being Tested in These Trials?
- Eligibility Requirements and How to Qualify for a Migraine Study
- Risks and Limitations You Should Know Before Enrolling
- The Economic Case for Participating in Migraine Research
- What the Migraine Clinical Trial Pipeline Looks Like Going Forward
- Conclusion
- Frequently Asked Questions
How Much Do Migraine Studies Actually Pay Participants?
Compensation for migraine clinical trials varies widely based on how involved the study is. A straightforward trial requiring a few office visits and a daily symptom diary might pay $100 to $450, while a multi-phase study with frequent blood draws, imaging, and months of follow-up can reach $800 or more. The payments are typically structured as reimbursement for your time and travel rather than a flat fee for participation, which means you generally get paid incrementally as you complete each visit. Miss a visit, and your total compensation drops accordingly. Pediatric studies tend to pay more because they require a parent or guardian to accompany the child, effectively compensating two people’s time. Discovery Clinical Trials in San Antonio, for instance, offers up to $1,680 for full participation in their pediatric migraine studies.
By comparison, Santos Research Center’s adult study in Tampa caps out at $450. The difference is not arbitrary. Pediatric trials involve additional consent procedures, more frequent monitoring, and longer observation windows, all of which demand more of your schedule. One thing worth noting is that compensation should never be the sole reason you enroll. The monetary payments are real, but they are designed to offset inconvenience, not to serve as income. If a study advertises unusually high payments with minimal requirements, that is a red flag worth investigating before you hand over your medical history.
Where to Find Paid Migraine Clinical Trials Recruiting Right Now
The most reliable starting point is ClinicalTrials.gov, the federal database maintained by the National Institutes of Health. It lists hundreds of migraine studies, and you can filter results by “Recruiting” status to see only trials that are actively enrolling participants. From there, you can narrow by location, age group, and study phase. The interface is not particularly user-friendly, but it is the most comprehensive and trustworthy source available. Beyond that, several research organizations are running migraine trials across the country. Pfizer currently operates migraine studies at more than 150 centers throughout the United States.
Velocity Clinical Research conducts trials at locations nationwide, and CNS Healthcare has enrolling paid migraine studies at multiple sites. If you are in Texas, you have a notable advantage. The state currently has 24 active migraine clinical trials spread across Houston, Dallas, San Antonio, and Austin, making it one of the most active regions for headache research. However, if you live in a rural area or a state with fewer research institutions, your options shrink considerably. Many trials require in-person visits every two to four weeks, and travel reimbursement does not always cover the actual cost of driving several hours each way. Some studies have begun incorporating telemedicine components, but the majority still require you to show up in person for key assessments. Before applying, confirm the location and visit schedule to make sure the logistics are realistic for your situation.
What New Migraine Treatments Are Being Tested in These Trials?
The migraine treatment landscape has shifted dramatically in recent years, and the drugs moving through clinical trials right now reflect that momentum. Eight CGRP-targeting drugs are now FDA-approved for migraine prevention and treatment, and the American Headache Society recommends them as first-line preventive therapy. This is a significant change from even five years ago, when older medications like topiramate and beta-blockers were the default starting point. Among the newer approvals, fremanezumab (sold as Ajovy) received FDA approval in August 2025 as the first anti-CGRP preventive treatment for pediatric episodic migraine in patients aged six and older weighing at least 45 kilograms. AXS-07 (Symbravo) is another recent addition, an oral acute migraine treatment that showed effectiveness in the MOMENTUM and INTERCEPT trials.
STS101 (Atzumi), a dihydroergotamine nasal powder, was also approved for acute migraine after demonstrating significant pain relief within two hours. These approvals matter for trial participants because follow-on studies and expanded-indication trials often recruit specifically for drugs that have recently cleared regulatory hurdles. Looking further ahead, Lundbeck’s Lu AG09222 is set to begin a phase 3 trial in the second half of 2026, and Biohaven’s BHV-2100, a TRPM3 antagonist for acute migraine, is currently in a pivotal Phase 2 trial. If you enroll in a trial testing one of these pipeline drugs, you would be among the first people to try a treatment that is not yet available to the public. That access is one of the non-monetary benefits participants often overlook.
Eligibility Requirements and How to Qualify for a Migraine Study
Most migraine clinical trials require a confirmed diagnosis of migraine, typically with a history of four or more migraine days per month. This threshold is important because researchers need participants whose symptoms are frequent enough to measure a drug’s effect over the study period. If you experience migraines only once or twice a month, you may not meet the inclusion criteria for many trials, though some studies do enroll people with lower-frequency episodic migraine. The standard age range for adult studies is 18 to 65, though some extend to 17 at the lower end or have no upper cap. Pediatric trials generally accept participants aged 6 to 17. You will also need to disclose your current medications, as most studies exclude participants taking certain drugs that could interfere with the results.
This is one of the trickier aspects of enrollment. If you are already on a CGRP inhibitor, for example, a trial testing a competing CGRP drug will almost certainly exclude you. You may be asked to go through a washout period where you stop your current medication before starting the trial, which is a tradeoff worth thinking through carefully with your doctor. The Teva Migraine Pregnancy Registry is a notable exception to the standard trial format. It is currently enrolling women aged 18 to 45 to study the effects of migraine medications during pregnancy, with enrollment open through September 2026. This is an observational study rather than an interventional one, meaning participants continue their prescribed treatments and report outcomes rather than testing a new drug. Compensation structures for observational studies differ from interventional trials, so confirm the specifics before enrolling.
Risks and Limitations You Should Know Before Enrolling
The most significant risk in any clinical trial is that you might receive a placebo instead of the active drug. Many migraine studies are randomized and double-blinded, meaning neither you nor the research staff know whether you are getting the real treatment. If your migraines are severe and you are relying on the trial for relief, going weeks or months on a placebo can be genuinely difficult. Some trials use an “add-on” design where everyone continues their existing treatment and the study drug is layered on top, which reduces this concern, but not all studies are structured that way. Side effects are another reality to weigh.
A 2025 FDA adverse event analysis flagged Raynaud phenomenon, a condition causing reduced blood flow to the fingers and toes, as a disproportionately reported side effect across multiple CGRP agents. This does not mean every participant will experience it, but it is the kind of emerging signal that you should discuss with the study investigators before enrolling. You have the right to ask about all known and suspected side effects, and reputable research sites will be transparent about them. Finally, participation is voluntary and can be withdrawn at any time, but dropping out mid-study can affect your compensation. Most trials pay per completed visit, so if you leave after three of eight scheduled appointments, you receive payment only for those three. There is no penalty for withdrawing, but understand the financial structure upfront so your expectations are calibrated correctly.
The Economic Case for Participating in Migraine Research
Migraine costs U.S. employers an estimated $12 billion annually in lost productivity, and individual sufferers can lose up to $13,000 per year in reduced work output on top of their direct medical expenses. One in five working-age adults between 18 and 54 report severe headaches or migraine in the past three months, making this one of the most economically significant neurological conditions in the workforce.
For participants, the financial math can make sense beyond just the study payment. Free study-related medical care, free medication, and regular monitoring by specialists add up, particularly for people who are underinsured or whose current treatments are not covered well by their plan. A study paying $800 over several months might seem modest, but when you factor in the value of the medical care provided at no cost, the effective compensation can be substantially higher.
What the Migraine Clinical Trial Pipeline Looks Like Going Forward
The next few years should bring a wave of new enrollment opportunities for migraine sufferers. With Lundbeck’s Phase 3 trial for Lu AG09222 launching in late 2026 and Biohaven pushing BHV-2100 through pivotal studies, the demand for qualified participants is likely to increase. Pharmaceutical companies are also expanding their trial networks, as evidenced by Pfizer’s presence at over 150 U.S.
centers, which means geographic accessibility should gradually improve. The broader shift toward CGRP-targeting therapies as first-line treatments is reshaping which studies get funded and how aggressively they recruit. As more of these drugs reach the market, expect to see trials focused on comparative effectiveness, meaning studies that test one approved drug against another to determine which works better for specific patient populations. These head-to-head trials often come with competitive compensation because companies are motivated to demonstrate superiority, and they need enough participants to produce statistically meaningful results.
Conclusion
Paid migraine clinical trials represent a legitimate way to access cutting-edge treatments while earning $100 to over $1,000 in compensation for your time. The key resources for finding active studies are ClinicalTrials.gov, major research networks like Pfizer, Velocity Clinical Research, and CNS Healthcare, and regional research centers such as Santos Research Center and Discovery Clinical Trials. Every study also includes no-cost medical care and medication, which adds real value beyond the cash payment.
Before you enroll, confirm that you meet the eligibility criteria, understand the visit schedule and time commitment, ask about placebo odds and known side effects, and clarify exactly how and when compensation is paid. Talk to your neurologist or primary care physician about whether a specific trial makes sense given your current treatment plan. Participation is always voluntary, and the right study can give you early access to a treatment that might not be publicly available for years.
Frequently Asked Questions
Do I have to stop my current migraine medication to join a clinical trial?
It depends on the study. Many trials require a washout period where you discontinue certain medications before starting the investigational drug. Others allow you to continue your current treatment and add the study drug on top. Always ask the research coordinator about medication requirements before enrolling.
Will I definitely receive the actual drug being tested?
Not necessarily. Many migraine trials are placebo-controlled, meaning some participants receive an inactive treatment. The odds vary by study design, but common ratios are 2:1 or 3:1 in favor of the active drug. The informed consent document will specify the randomization ratio.
How long do most migraine clinical trials last?
Most run between 8 weeks and 6 months, though some long-term safety studies extend to a year or more. Shorter studies typically involve fewer visits and lower total compensation, while longer ones pay more but demand a greater time commitment.
Can children participate in paid migraine studies?
Yes. Some trials accept participants as young as 6 years old, such as studies testing fremanezumab (Ajovy), which received FDA approval in August 2025 for pediatric episodic migraine. Pediatric studies often pay more, with some offering up to $1,680 for full participation, to compensate for the additional time required from parents.
Are migraine clinical trials safe?
All FDA-regulated clinical trials go through institutional review board approval and follow strict safety protocols. However, risks do exist. For example, a 2025 FDA adverse event analysis identified Raynaud phenomenon as a disproportionately reported side effect among CGRP-targeting drugs. You should discuss all known risks with the study team before consenting.
Do I need health insurance to participate?
No. Study-related medical care and medication are provided at no cost to participants regardless of insurance status. However, any medical care unrelated to the study remains your financial responsibility.
